HC notice to JBD Life on Dr Reddy's plea for cancelling 'rozatan' trademark
This story was originally published at 21:09 IST on 2 February 2026
Register to read our real-time news.Informist, Monday, Feb. 2, 2026
NEW DELHI – The Delhi High Court has issued notices to JBD Life Sciences Pvt. Ltd. and the trademarks registry on Dr. Reddy's Laboratories Ltd.'s plea seeking cancellation of "Rozatan" trademark registered in favour of JBD Life. "Replies be filed within four weeks from the date of service with an advance copy to the learned counsel for the petitioner. Rejoinder thereto, shall be filed within two weeks thereafter with an advance copy to the learned counsel for the respondents," said the high court. It will hear Dr. Reddy's Laboratories' plea against JBD Life next on May 6.
Dr. Reddy's manufacturers Rozat 10 tablets that belong to a group of medicines called statins. It is used to lower cholesterol and triglyceride levels and reduce the risk of heart disease. However, JBD Life Sciences got trademark registration for its "Rozatan" mark, whose drug is also used to treat several types of dyslipidemias, an abnormal amount of cholesterol and triglycerides in the blood, often resulting from unhealthy diets, obesity, sedentary lifestyles, or genetics.
Earlier, the trademarks registry had registered JBD Life Sciences' "Rozatan" trademark under class 5 registration, which protects trademarks under pharmaceutical, veterinary, sanitary preparations, dietary supplements, and baby food. Challenging the trademarks registry's order, Dr. Reddy's moved the high court.
Monday, shares of Dr. Reddy's Laboratories ended 0.3% higher at INR 1,182.50 on the National Stock Exchange. End
Reported by Surya Tripathi
Edited by Akul Nishant Akhoury
For users of real-time market data terminals, Informist news is available exclusively on the NSE Cogencis WorkStation.
Cogencis news is now Informist news. This follows the acquisition of Cogencis Information Services Ltd. by NSE Data & Analytics Ltd., a 100% subsidiary of the National Stock Exchange of India Ltd. As a part of the transaction, the news department of Cogencis has been sold to Informist Media Pvt. Ltd.
Informist Media Tel +91 (22) 6985-4000
Send comments to feedback@informistmedia.com
© Informist Media Pvt. Ltd. 2026. All rights reserved.
To read more please subscribe
Share this Story:
